drugset / Trial / NCT06783829

A Study of SHR-4394 Injection in Subjects With Prostate Cancer

NCT06783829

Phase 1 Recruiting 240 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.

Timeline

Start
2025-01-22
Primary completion
2027-03
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR4394 Unknown

Indications